Back to Sites FAMCRU CRS Site Number 8950 Address FAMCRU Ward J8 Tygerberg Hospital Francie van Zijl Drive Parow Valley Tygerberg, Western Cape Province 7505 South Africa IMPAACT Members at this Site Jacqueline Jacobs CAB Member Siphokazi Khonkwane CAB Member Jeanne De Jager CRS Coordinator Shaun Barnabas CRS Leader Mark Cotton CRS Leader Ronell Arendze CRS Staff Jacky Crisp CRS Staff Jeanne De Jager CRS Staff Els Dobbels CRS Staff George Fourie CRS Staff Lindee Ganger CRS Staff Leonie Groepies CRS Staff Morne Isaacs CRS Staff Veronica Matroos CRS Staff Bongiwe Mbotho CRS Staff Nwabisa Mtambeka CRS Staff Susan Purchase CRS Staff Helena Rabie CRS Staff Magdel Rossouw CRS Staff Kurt Smith CRS Staff Marie Theunissen CRS Staff Warren Zimri CRS Staff Jeannine du Bois CTU Coordinator Anneke Hesseling CTU Principal Investigator Donna Germuga DAIDS PO Maria Groenewald Investigator Barbara Laughton Investigator Simon Schaaf Investigator Gerhard Theron Investigator Lindie Rossouw Pediatrician Catherine Andrea Pharmacist Marlize Smuts Pharmacist of Record Marjie van Schalkwyk Principal Investigator Lilly Hoorn Research Nurse Andrea Gutschmidt Staff Sharifah Sylvester Staff Marjie van Schalkwyk Study Coordinator Studies at this Site P1026S: PK in Pregnancy DAIDS Number Therapeutics Research Area Treatment Study Status Closed to Follow Up P1060: NNRTI-Based vs. PI-Based ART in Infants Exposed/Not Exposed to NVP for PMTCT DAIDS Number 10166 Research Area Treatment Study Status Concluded P1066: Raltegravir Safety, Tolerability, PK, & Antiretroviral Activity DAIDS Number 10495 Research Area Treatment Study Status Concluded P1070: EFV in HIV-infected and HIV/TB Co-infected Subjects DAIDS Number 10633 Research Area Treatment Study Status Concluded P1073: Study of Immune Reconstitution Inflammatory Syndrome (IRIS) for International Sites Initiating Highly Active Antiretroviral Therapy (HAART) in Infants and Children <72 Months of Age DAIDS Number 10655 Research Area Other Study Status Concluded P1078: TB APPRISE: TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed infants DAIDS Number 10732 Research Area Tuberculosis P1083: Kaletra/Aluvia PK study DAIDS Number 10787 Research Area Treatment Study Status Concluded P1084s: Maternal Infant TDF Toxicity Safety DAIDS Number 10790 Research Area Therapeutics Study Status Closed to Follow Up P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Therapeutics 1077BF: PROMISE 1077BF DAIDS Number 10777 Research Area Prevention Study Status Participants Off Study and Primary Analysis Completed Pagination Current page 1 Page 2 Page 3 Next page Next
P1026S: PK in Pregnancy DAIDS Number Therapeutics Research Area Treatment Study Status Closed to Follow Up
P1060: NNRTI-Based vs. PI-Based ART in Infants Exposed/Not Exposed to NVP for PMTCT DAIDS Number 10166 Research Area Treatment Study Status Concluded
P1066: Raltegravir Safety, Tolerability, PK, & Antiretroviral Activity DAIDS Number 10495 Research Area Treatment Study Status Concluded
P1070: EFV in HIV-infected and HIV/TB Co-infected Subjects DAIDS Number 10633 Research Area Treatment Study Status Concluded
P1073: Study of Immune Reconstitution Inflammatory Syndrome (IRIS) for International Sites Initiating Highly Active Antiretroviral Therapy (HAART) in Infants and Children <72 Months of Age DAIDS Number 10655 Research Area Other Study Status Concluded
P1078: TB APPRISE: TB Ante vs. Postpartum Prevention with INH in HIV Seropositive mothers and their Exposed infants DAIDS Number 10732 Research Area Tuberculosis
P1084s: Maternal Infant TDF Toxicity Safety DAIDS Number 10790 Research Area Therapeutics Study Status Closed to Follow Up
P1093: PK, Safety, Tolerability and Antiviral Activity of Dolutegravir DAIDS Number 11773 Research Area Therapeutics
1077BF: PROMISE 1077BF DAIDS Number 10777 Research Area Prevention Study Status Participants Off Study and Primary Analysis Completed